EsoBiotec
2025
$1.0B
Why
AstraZeneca acquired Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology that delivers CAR-T genetic modifications directly within the patient's body, eliminating the need for ex vivo manufacturing. The strategic rationale was evaluated against alternative uses of capital including share buybacks and debt reduction, with the board concluding that the acquisition created superior long-term value.
Impact
If successful, in vivo cell therapy could democratize access to CAR-T treatments by removing the manufacturing complexity, cost, and time delays that currently limit these therapies to specialized treatment centres. The integration required significant management attention and organizational restructuring, but the long-term strategic benefits have exceeded initial expectations.
Outcome
The acquisition was completed in March 2025, with EsoBiotec's platform integrated into AstraZeneca's early-stage oncology research. The transaction has been incorporated into AstraZeneca's broader portfolio and continues to contribute to the company's growth trajectory.